Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium.

Krasnick BA, Jin LX, Davidson JT 4th, Sanford DE, Ethun CG, Pawlik TM, Poultsides GA, Tran T, Idrees K, Hawkins WG, Chapman WC, Doyle MBM, Weber SM, Strasberg SM, Salem A, Martin RCG, Isom CA, Scoggins C, Schmidt CR, Shen P, Beal E, Hatzaras I, Shenoy R, Maithel SK, Fields RC.

J Surg Oncol. 2018 Mar;117(3):363-371. doi: 10.1002/jso.24836. Epub 2017 Dec 28.

2.

Identification of Patients for Adjuvant Therapy After Resection of Carcinoma of the Extrahepatic Bile Ducts: A Propensity Score-Matched Analysis.

Ecker BL, Vining CC, Roses RE, Maggino L, Lee MK, Drebin JA, Fraker DL, Vollmer CM Jr, Datta J.

Ann Surg Oncol. 2017 Dec;24(13):3926-3933. doi: 10.1245/s10434-017-6095-9. Epub 2017 Sep 26.

PMID:
28952140
3.

Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma.

Kim YS, Hwang IG, Park SE, Go SI, Kang JH, Park I, Oh SY, Ji JH, Song HN, Park SH, Kim ST, Park JO.

Cancer Chemother Pharmacol. 2016 May;77(5):979-85. doi: 10.1007/s00280-016-3014-x. Epub 2016 Mar 26.

PMID:
27017615
4.

Adjuvant concurrent chemoradiation therapy in patients with microscopic residual tumor after curative resection for extrahepatic cholangiocarcinoma.

Lee J, Kang SH, Noh OK, Chun M, Oh YT, Kim BW, Kim SW.

Clin Transl Oncol. 2018 Aug;20(8):1011-1017. doi: 10.1007/s12094-017-1815-y. Epub 2017 Dec 18.

PMID:
29256155
5.

The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium.

Bhutiani N, Scoggins CR, McMasters KM, Ethun CG, Poultsides GA, Pawlik TM, Weber SM, Schmidt CR, Fields RC, Idrees K, Hatzaras I, Shen P, Maithel SK, Martin RCG 2nd.

Surgery. 2018 Apr;163(4):726-731. doi: 10.1016/j.surg.2017.10.028. Epub 2018 Jan 3.

PMID:
29306541
6.

The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases.

de Jong MC, Marques H, Clary BM, Bauer TW, Marsh JW, Ribero D, Majno P, Hatzaras I, Walters DM, Barbas AS, Mega R, Schulick RD, Choti MA, Geller DA, Barroso E, Mentha G, Capussotti L, Pawlik TM.

Cancer. 2012 Oct 1;118(19):4737-47. doi: 10.1002/cncr.27492. Epub 2012 Mar 13.

7.

Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.

Zhang XF, Beal EW, Chakedis J, Chen Q, Lv Y, Ethun CG, Salem A, Weber SM, Tran T, Poultsides G, Son AY, Hatzaras I, Jin L, Fields RC, Buettner S, Scoggins C, Martin RCG, Isom CA, Idrees K, Mogal HD, Shen P, Maithel SK, Schmidt CR, Pawlik TM.

World J Surg. 2018 Sep;42(9):2919-2929. doi: 10.1007/s00268-018-4530-0.

PMID:
29404753
8.

The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts.

Tran Cao HS, Zhang Q, Sada YH, Chai C, Curley SA, Massarweh NN.

Cancer. 2018 Jan 1;124(1):74-83. doi: 10.1002/cncr.30968. Epub 2017 Aug 25.

9.

Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium.

Ethun CG, Lopez-Aguiar AG, Pawlik TM, Poultsides G, Idrees K, Fields RC, Weber SM, Cho C, Martin RC, Scoggins CR, Shen P, Schmidt C, Hatzaras I, Bentrem D, Ahmad S, Abbott D, Kim HJ, Merchant N, Staley CA, Kooby DA, Maithel SK.

J Am Coll Surg. 2017 Apr;224(4):406-413. doi: 10.1016/j.jamcollsurg.2016.12.006. Epub 2016 Dec 23.

PMID:
28017812
10.

The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas.

Kim YS, Oh SY, Go SI, Kang JH, Park I, Song HN, Ji JH, Hwang IG, Jang JS.

Cancer Chemother Pharmacol. 2017 Jan;79(1):99-106. doi: 10.1007/s00280-016-3206-4. Epub 2016 Dec 7.

PMID:
27928598
11.

Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.

Li T, Qin LX, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Tang ZY, Fan J.

Liver Int. 2014 Jul;34(6):953-60. doi: 10.1111/liv.12364. Epub 2013 Nov 20.

PMID:
24134199
12.

The prognostic importance of lymphovascular invasion in cholangiocarcinoma above the cystic duct: a new selection criterion for adjuvant therapy?

Patel SH, Kooby DA, Staley CA 3rd, Sarmiento JM, Maithel SK.

HPB (Oxford). 2011 Sep;13(9):605-11. doi: 10.1111/j.1477-2574.2011.00335.x. Epub 2011 Jul 26.

13.

Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis.

Reames BN, Bagante F, Ejaz A, Spolverato G, Ruzzenente A, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Itaru E, Pawlik TM.

HPB (Oxford). 2017 Oct;19(10):901-909. doi: 10.1016/j.hpb.2017.06.008. Epub 2017 Jul 17.

14.

Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma.

Dover LL, Oster RA, McDonald AM, DuBay DA, Wang TN, Jacob R.

HPB (Oxford). 2016 Oct;18(10):843-850. doi: 10.1016/j.hpb.2016.07.008. Epub 2016 Aug 16.

15.

Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium.

Beal EW, Wei L, Ethun CG, Black SM, Dillhoff M, Salem A, Weber SM, Tran T, Poultsides G, Son AY, Hatzaras I, Jin L, Fields RC, Buettner S, Pawlik TM, Scoggins C, Martin RC, Isom CA, Idrees K, Mogal HD, Shen P, Maithel SK, Schmidt CR.

HPB (Oxford). 2016 Nov;18(11):950-957. doi: 10.1016/j.hpb.2016.08.006. Epub 2016 Sep 24.

16.

Locoregional recurrence after curative intent resection for intrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy.

Song S, Kim K, Chie EK, Kim S, Park HJ, Yi NJ, Suh KS, Ha SW.

Clin Transl Oncol. 2015 Oct;17(10):825-9. doi: 10.1007/s12094-015-1312-0. Epub 2015 Jun 4.

PMID:
26041722
17.

Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins.

Glazer ES, Liu P, Abdalla EK, Vauthey JN, Curley SA.

J Gastrointest Surg. 2012 Sep;16(9):1666-71. doi: 10.1007/s11605-012-1935-1. Epub 2012 Jul 10.

18.

The prognosis after curative resection of gallbladder cancer with hilar invasion is similar to that of hilar cholangiocarcinoma.

Nasu Y, Tanaka E, Hirano S, Tsuchikawa T, Kato K, Matsumoto J, Shichinohe T, Kondo S.

J Hepatobiliary Pancreat Sci. 2012 May;19(3):274-80. doi: 10.1007/s00534-011-0439-9.

PMID:
21879321
19.

Surgical outcomes of 230 resected hilar cholangiocarcinoma in a single centre.

Song SC, Choi DW, Kow AW, Choi SH, Heo JS, Kim WS, Kim MJ.

ANZ J Surg. 2013 Apr;83(4):268-74. doi: 10.1111/j.1445-2197.2012.06195.x. Epub 2012 Sep 3.

PMID:
22943422
20.

Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence.

Ito F, Agni R, Rettammel RJ, Been MJ, Cho CS, Mahvi DM, Rikkers LF, Weber SM.

Ann Surg. 2008 Aug;248(2):273-9. doi: 10.1097/SLA.0b013e31817f2bfd.

PMID:
18650638

Supplemental Content

Support Center